China
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2012 1 377 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 44 (43–46) 3.2 (3.1–3.3)
Mortality (HIV+TB only) 1.2 (0.93–1.5) 0.08 (0.07–0.11)
Prevalence  (includes HIV+TB) 1 400 (1 200–1 600) 99 (86–113)
Incidence  (includes HIV+TB) 1 000 (880–1 100) 73 (64–82)
Incidence (HIV+TB only) 7.3 (6.4–8.2) 0.53 (0.47–0.6)
Case detection, all forms (%) 89 (79–100)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 316 332 (37) Relapse 31 784 (76)
Smear-negative 533 977 (62) Treatment after failure 2 281 (5)
Smear-unknown / not done 2 073 (<1) Treatment after default 738 (2)
Extrapulmonary 6 479 (<1) Other 7 014 (17)
Other 0 (0)      
Total new 858 861   Total retreatment 41 817  
           
Other (history unknown) 0        
Total new and relapse 890 645   Total cases notified 900 678  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.5 2.1 0.8
Age < 15 1 091 4 288 246
Laboratories 2012
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 3.7
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 95   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 95  
Retreatment 90  
TB/HIV 2012 Number (%)
TB patients with known HIV status 309 385 (34)
HIV-positive TB patients 5 866 (2)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 3 454 (59)
HIV-positive people screened for TB 294 795  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 5.7 (4.5–7) 26 (22–30)
MDR-TB cases among notified pulmonary
TB cases
49 000 (38 000–60 000) 11 000 (9 000–12 000)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 11 472 (4%) 4 861 (12%) 16 333
Laboratory-confirmed MDR-TB cases 826 1 678 3 007
Patients started on MDR-TB treatment     1 906
Financing TB control 2013
National TB programme budget (US$ millions) 359
% Funded domestically 74%
% Funded internationally 11%
% Unfunded 15%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data